Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex

Tralokinumab, a fully human mAb specifically targeting the IL-13 cytokine, has demonstrated clinical efficacy and safety in patients with moderate-to-severe atopic dermatitis. Tralokinumab binds IL-13 with high affinity, which prevents the interaction of IL-13 with IL-13Rα1 and subsequent signaling....

Descripción completa

Detalles Bibliográficos
Autores principales: Tollenaere, Maxim A.X., Mølck, Christina, Henderson, Ian, Pollack, Scott, Addis, Philip, Petersen, Helle Heibroch, Norsgaard, Hanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405097/
https://www.ncbi.nlm.nih.gov/pubmed/37554517
http://dx.doi.org/10.1016/j.xjidi.2023.100214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405097/
https://www.ncbi.nlm.nih.gov/pubmed/37554517
http://dx.doi.org/10.1016/j.xjidi.2023.100214

Ejemplares similares